Literature DB >> 222502

A liquid chromatography-assisted assay for angiotensin-converting enzyme (peptidyl dipeptidase) in serum.

S G Chiknas.   

Abstract

I describe modification of the spectrophotometric assay described by Cushman and Cheung [biochem. Pharmacol. 20, 1637 (1971)] for serum angiotensin-converting enzyme, with use of "high-pressure" liquid chromatography to measure the hippuric acid end product. After reaction of 10 microL of untreated serum with the angiotensin-converting enzyme substrate analog hippuryl-L-histidyl-L-leucine, the hippuric acid produced is extracted into ethyl acetate and quantitated, relative to an added internal standard, by liquid chromatography. Total chromatographic running time is 3 min per sample, with a within-run CV of 4.3% and a day-to-day CV of 6.6%, for aliquots of plasma supplemented with 1 mmol of hippuric acid per liter. The measurements are linear for hippuric acid in amounts up to 20 nmol per assay. The presence of large quantities of lipid in the serum did not affect the accuracy of the determination.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222502

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  25 in total

1.  Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

2.  A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.

Authors:  A D Bainbridge; R J MacFadyen; K R Lees; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

3.  The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril.

Authors:  N J Macdonald; A Sioufi; C A Howie; J R Wade; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

4.  A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril.

Authors:  N J Macdonald; H L Elliott; D M Hughes; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

5.  Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding.

Authors:  K R Lees; A W Kelman; J L Reid; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

6.  Serum angiotensin-converting enzyme and lysosomal enzymes in asbestosis.

Authors:  M S Huuskonen; J Jävisalo; H Koskinen; H Kivistö
Journal:  Lung       Date:  1986       Impact factor: 2.584

7.  Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  A A Ajayi; N Hockings; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

8.  The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis.

Authors:  H H Tsai; K R Lees; C W Howden; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

9.  Transpulmonary pharmacokinetics of an ACE inhibitor (perindoprilat) in man.

Authors:  R J MacFadyen; K R Lees; J D Gemmill; W S Hillis; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

10.  Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br Heart J       Date:  1991-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.